-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On September 28, 2021, ViiV Healthcare announced that the US FDA has granted Cabotegravir's New Drug Application (NDA) priority review as a long-acting injection therapy for HIV pre-exposure prevention (PrEP)
Cabotvir is an innovative antiviral drug developed by ViiV Healthcare
The new drug application is based on the results of two phase 2b/3 clinical trials
▲The molecular structure of Cabotvir (picture source: PubChem)
In terms of safety, the most common adverse reactions (all grades) observed were injection site reactions, diarrhea, headache, fever, fatigue, sleep disturbance, nausea, dizziness, flatulence and abdominal pain
Reference materials:
[1] FDA grants Priority Review to ViiV Healthcare's New Drug Application for cabotegravir long-acting for prevention of HIV.